Neurogene (NASDAQ:NGNE) Price Target Raised to $72.00 at Leerink Partners

Neurogene (NASDAQ:NGNE – Free Report) had its price target hoisted by Leerink Partners from $45.00 to $72.00 in a research report released on Tuesday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock. Several other analysts also recently weighed in on the company. Robert W. Baird boosted their target price on Neurogene from […]

Leave a Reply

Your email address will not be published.

Previous post EVgo Reports Record Third Quarter 2024 Results
Next post Insider Selling: The Williams Companies, Inc. (NYSE:WMB) CAO Sells 7,951 Shares of Stock